TY - JOUR
T1 - Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan
AU - Ogino, Haruei
AU - Morikubo, Hiromu
AU - Fukaura, Keita
AU - Okui, Tasuku
AU - Gardiner, Sean
AU - Sugiyama, Naonobu
AU - Yoshii, Noritoshi
AU - Kawaguchi, Tsutomu
AU - Chen, Haoqian
AU - Nonnenmacher, Edward
AU - Setoguchi, Soko
AU - Nakashima, Naoki
AU - Kobayashi, Taku
N1 - Funding Information:
HO, KF, TO, and NN have received funding from Pfizer Inc to attend study‐related meetings. HM has received funding from Pfizer Inc to attend study‐related meetings and has received research funding from the Japan Foundation of Applied Enzymology. SG, NS, and NY are employees and stockholders of Pfizer Inc. TKa was formerly employed by Pfizer Inc. HC and EN have no potential conflict of interest to declare. SS has served as a member of a US FDA advisory committee; has served as a consultant for Medtronic, Merck, and Pfizer Inc; and has received research funding from Bristol‐Myers Squibb, the Cystic Fibrosis Foundation, Daiichi Sankyo, the National Institutes of Health, the Patient‐Centered Outcomes Research Institute, Pfizer Inc, and Pfizer Japan. TKo has received personal fees from AbbVie GK, Ajinomoto Pharma, Alfresa Pharma, Asahi Kase Medical, Astellas, Celltrion, Covidien, EA Pharma Co Ltd, Eisai Co Ltd, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen, JIMRO Co Ltd, Kyorin Pharmaceutical Co Ltd, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kyaku, Pfizer Inc, Takeda Pharmaceutical, Thermo Scientific, and ZERIA; grants from AbbVie GK, Alfresa Pharma, Asahi Kasei Medical, EA Pharma Co Ltd, Kyorin Pharmaceutical Co Ltd, Mochida Pharmaceutical, Nippon Kyaku, Otsuka Holdings Co Ltd, Thermo Fisher Scientific, and ZERIA; and funding from Pfizer Inc to attend study‐related meetings. Conflict of interest:
Funding Information:
This work was sponsored by Pfizer Japan Inc. Financial support:
Funding Information:
Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications, and Kirsteen Munn, PhD, on behalf of CMC Connect, and was funded by Pfizer Japan Inc, Tokyo, Japan in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015; 163: 461–464). The authors thank Dr Takehiro Torisu (Department of Medical and Clinical Science, Graduate School of Medical Sciences, Kyushu University) for the use of the data generated within his department.
Funding Information:
Medical writing support, under the guidance of the authors, was provided by Helen Findlow, PhD, CMC Connect, McCann Health Medical Communications, and Kirsteen Munn, PhD, on behalf of CMC Connect, and was funded by Pfizer Japan Inc, Tokyo, Japan in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med 2015; 163: 461–464). The authors thank Dr Takehiro Torisu (Department of Medical and Clinical Science, Graduate School of Medical Sciences, Kyushu University) for the use of the data generated within his department.
Publisher Copyright:
© 2021 Pfizer Inc. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
PY - 2022/3
Y1 - 2022/3
N2 - Background and Aim: The prevalence of ulcerative colitis (UC) is increasing in Japan. Validated claims-based definitions are required to investigate the epidemiology of UC and its treatment and disease course in clinical practice. This study aimed to develop a claims-based algorithm for UC in Japan. Methods: A committee of epidemiologists, gastroenterologists, and internal medicine physicians developed a claims-based definition for UC, based on diagnostic codes and claims for UC treatments, procedures (cytapheresis), or surgery (postoperative claims). Claims data and medical records for a random sample of 200 cases per site at two large tertiary care academic centers in Japan were used to calculate the positive predictive value (PPV) of the algorithm for three gold standards of diagnosis, defined as physician diagnosis in the medical records, adjudicated cases, or registration in the Japanese Intractable Disease Registry (IDR). Results: Overall, 1139 claims-defined UC cases were identified. Among 393 randomly sampled cases (mean age 44; 48% female), 94% had received ≥ 1 systemic treatment (immunosuppressants, tumor necrosis factor inhibitors, corticosteroids, or antidiarrheals), 7% had cytapheresis, and 7% had postoperative claims. When physician diagnosis was used as a gold standard, PPV was 90.6% (95% confidence interval [CI]: 87.7–93.5). PPV with expert adjudication was also 90.6% (95% CI: 87.7–93.5). PPVs with enrollment in the IDR as gold standard were lower at 41.5% (95% CI: 36.6–46.3) due to incomplete case registration. Conclusions: The claims-based algorithm developed for use in Japan is likely to identify UC cases with high PPV for clinical studies using administrative claims databases.
AB - Background and Aim: The prevalence of ulcerative colitis (UC) is increasing in Japan. Validated claims-based definitions are required to investigate the epidemiology of UC and its treatment and disease course in clinical practice. This study aimed to develop a claims-based algorithm for UC in Japan. Methods: A committee of epidemiologists, gastroenterologists, and internal medicine physicians developed a claims-based definition for UC, based on diagnostic codes and claims for UC treatments, procedures (cytapheresis), or surgery (postoperative claims). Claims data and medical records for a random sample of 200 cases per site at two large tertiary care academic centers in Japan were used to calculate the positive predictive value (PPV) of the algorithm for three gold standards of diagnosis, defined as physician diagnosis in the medical records, adjudicated cases, or registration in the Japanese Intractable Disease Registry (IDR). Results: Overall, 1139 claims-defined UC cases were identified. Among 393 randomly sampled cases (mean age 44; 48% female), 94% had received ≥ 1 systemic treatment (immunosuppressants, tumor necrosis factor inhibitors, corticosteroids, or antidiarrheals), 7% had cytapheresis, and 7% had postoperative claims. When physician diagnosis was used as a gold standard, PPV was 90.6% (95% confidence interval [CI]: 87.7–93.5). PPV with expert adjudication was also 90.6% (95% CI: 87.7–93.5). PPVs with enrollment in the IDR as gold standard were lower at 41.5% (95% CI: 36.6–46.3) due to incomplete case registration. Conclusions: The claims-based algorithm developed for use in Japan is likely to identify UC cases with high PPV for clinical studies using administrative claims databases.
KW - algorithm
KW - claims database
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85120008341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120008341&partnerID=8YFLogxK
U2 - 10.1111/jgh.15732
DO - 10.1111/jgh.15732
M3 - Article
C2 - 34738649
AN - SCOPUS:85120008341
SN - 0815-9319
VL - 37
SP - 499
EP - 506
JO - Journal of Gastroenterology and Hepatology (Australia)
JF - Journal of Gastroenterology and Hepatology (Australia)
IS - 3
ER -